摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-(3-chloro-4-fluorophenyl)-3-(pyridin-4-yl)-1H-pyrrole | 811806-88-9

中文名称
——
中文别名
——
英文名称
2-(3-chloro-4-fluorophenyl)-3-(pyridin-4-yl)-1H-pyrrole
英文别名
4-[2-(3-chloro-4-fluorophenyl)-1H-pyrrol-3-yl]pyridine
2-(3-chloro-4-fluorophenyl)-3-(pyridin-4-yl)-1H-pyrrole化学式
CAS
811806-88-9
化学式
C15H10ClFN2
mdl
——
分子量
272.709
InChiKey
HSTVJTZALKGLEH-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.7
  • 重原子数:
    19
  • 可旋转键数:
    2
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    28.7
  • 氢给体数:
    1
  • 氢受体数:
    2

反应信息

点击查看最新优质反应信息

文献信息

  • CYCLIC TERTIARY AMINE COMPOUND
    申请人:Sankyo Company, Limited
    公开号:EP1632488A1
    公开(公告)日:2006-03-08
    The present invention provides a cyclic tertiary amine compound which is capable of inhibiting the production of inflammatory cytokines. It is either a compound having a structure represented by the following general formula (I): (wherein A represents an optionally substituted trivalent group derived from pyrimidine, pyrrole, or the like; R1 represents an aryl or a heteroaryl group which may optionally be substituted; R2 represents a heteroaryl group which may optionally be substituted; and R3 represents a cyclic tertiary amino group) or a pharmacologically acceptable salt of the compound.
    本发明提供了一种能够抑制炎症细胞因子产生的环状三级胺化合物。它是具有以下一般式(I)所表示结构的化合物:(其中A表示从嘧啶、吡咯等衍生的可选择取代的三价基团;R1表示可能被取代的芳基或杂环芳基团;R2表示可能被取代的杂环芳基团;R3表示环状三级胺基团),或该化合物的药理学可接受的盐。
  • Bicyclic unsaturated tertiary amine compounds
    申请人:Kimura Tomio
    公开号:US20050159444A1
    公开(公告)日:2005-07-21
    A bicyclic unsaturated tertiary amine compound capable of inhibiting the production of inflammatory cytokines. The compound has the following formula (I): wherein A represents pyrrole or pyrazole, R 1 represents an aryl group or a heteroaryl group which may be substituted, R 2 represents a heteroaryl group which may be substituted, and R 3 represents an indolizine group, or a pharmacologically acceptable salt thereof, a pharmacologically acceptable ester thereof or a pharmacologically acceptable derivative thereof.
    一种双环不饱和三级胺化合物,能够抑制炎症细胞因子的产生。该化合物的化学式如下(I):其中A代表吡咯或吡唑,R1代表取代的芳基或杂环基,R2代表取代的杂环基,R3代表吲哚啉基,或其药学上可接受的盐、酯或衍生物。
  • Cyclic tertiary amine compound
    申请人:Kimura Tomio
    公开号:US20070049620A1
    公开(公告)日:2007-03-01
    A cyclic tertiary amine compound which is capable of inhibiting the production of inflammatory cytoines. The compound having a structure represented by the following formula (I): wherein A represents an optionally substituted trivalent group which is benzene, pyrimidine, pyrrole, pyridine, pyridazine, furan, thiopene, pyrazole, imidazole, isoxazole or isothiazole; R 1 represents an aryl or a heteroaryl group, which is unsubstituted or substituted; R 2 represents a heteroaryl group which is unsubtituted or substituted; and R 3 represents a cyclic tertiary amino group, or a pharmacologically acceptable salt of the compound.
    一种环状三级胺化合物,能够抑制炎症细胞因子的产生。该化合物具有以下式子(I)所表示的结构:其中A代表苯、嘧啶、吡咯、吡啶、吡嗪、呋喃、噻吩、吡唑、咪唑、异恶唑或异硫唑的可选取代三价基团;R1代表非取代或取代的芳基或杂环基团;R2代表非取代或取代的杂环基团;R3代表环状三级胺基团,或该化合物的药理学上可接受的盐。
  • BICYCLIC UNSATURATED TERTIARY AMINE COMPOUND
    申请人:Sankyo Company, Limited
    公开号:EP1541571A1
    公开(公告)日:2005-06-15
    The present invention provides a bicyclic unsaturated tertiary amine compound capable of inhibiting the production of inflammatory cytokines. A compound of the following formula (1): (wherein, A represents pyrrole or pyrazole, R1 represents an aryl group or a heteroaryl group which may be substituted, R2 represents a heteroaryl group which may be substituted, and R3 represents an indolizine group), or a pharmacologically acceptable salt thereof, a pharmacologically acceptable ester thereof or other pharmacologically acceptable derivative thereof.
    本发明提供了一种能够抑制炎症细胞因子产生的双环不饱和叔胺化合物。 一种下式(1)的化合物: (其中、 A代表吡咯或吡唑,R1代表芳基或可被取代的杂芳基,R2代表可被取代的杂芳基,R3代表吲嗪基),或其药理学上可接受的盐、药理学上可接受的酯或其它药理学上可接受的衍生物。
  • EP1541571
    申请人:——
    公开号:——
    公开(公告)日:——
查看更多